Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    SMAD4
Show Display Options
Rank Status Study
1 Recruiting French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperplastic Polyposis
Condition: Quality of Life
Interventions: Other: Procedure surgery behavioral and genetic diagnosis;   Procedure: quality of life after different type of surgery
2 Recruiting Pancreatico-biliary Tumor Mutation Profiling in Bile Samples
Condition: Cholangiocarcinoma, Cancer of the Head of the Pancreas
Interventions: Biological: bile sample analysis;   Biological: biochemical markers, VEGF and MMPs, in bile samples
3 Terminated High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Pancreatic Adenocarcinoma;   Stage III Pancreatic Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Capecitabine;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
4 Recruiting MR Guided Dose Escalated RT + Concurrent Chemotherapy in Unresectable Pancreatic Cancer
Condition: Unresectable Pancreatic Cancer
Interventions: Radiation: Radiation Therapy;   Drug: Concurrent chemotherapy (Gemcitabine, Capecitabine)
5 Recruiting Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
Conditions: Breast Cancer;   Ovarian Cancer;   Colorectal Cancer;   Pediatric Cancers;   Multiple Primary Malignant Tumours
Intervention: Genetic: Genetic analysis
6 Recruiting Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
Condition: Borderline Resectable Pancreatic Cancer
Interventions: Drug: gemcitabine/nab-paclitaxel;   Drug: mFOLFIRINOX

Study has passed its completion date and status has not been verified in more than two years.